Moleculin Biotech CS (MBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -21,763 | -29,769 | -29,025 | -15,894 | -17,355 |
| Depreciation Amortization | 126 | 127 | 130 | 164 | 200 |
| Other Working Capital | 231 | 1,622 | 224 | 1,038 | -41 |
| Other Operating Activity | -2,456 | 4,429 | 1,032 | -4,259 | -575 |
| Operating Cash Flow | $-23,862 | $-23,591 | $-27,639 | $-18,951 | $-17,771 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -13 | -124 | -67 | -19 | -374 |
| Investing Cash Flow | $-13 | $-124 | $-67 | $-19 | $-374 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 4,661 | 4,166 | N/A | 74,747 | 22,566 |
| Other Financing Activity | -26 | -25 | -23 | -23 | -17 |
| Financing Cash Flow | $4,635 | $4,141 | $-23 | $74,724 | $22,549 |
| Exchange Rate Effect | -32 | -21 | -29 | -24 | 34 |
| Beginning Cash Position | 23,550 | 43,145 | 70,903 | 15,173 | 10,735 |
| End Cash Position | 4,278 | 23,550 | 43,145 | 70,903 | 15,173 |
| Net Cash Flow | $-19,272 | $-19,595 | $-27,758 | $55,730 | $4,438 |
| Free Cash Flow | |||||
| Operating Cash Flow | -23,862 | -23,591 | -27,639 | -18,951 | -17,771 |
| Capital Expenditure | -13 | -124 | -67 | -19 | -376 |
| Free Cash Flow | -23,875 | -23,715 | -27,706 | -18,970 | -18,147 |